ReviewHuman vaccines & immunotherapeutics2026
Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to systematically analyze the research status, hotspots, and trends of oncolytic virotherapy (OV) for hepatocellular carcinoma (HCC) from 2000 to mid-2025, scientifically predict future directions, facilitate clinical translation, and provide a reference for subsequent studies in this field. Based on the Web of Science Core Collection and Scopus databases, bibliometric methods were adopted combined with visualization analyses using R software (version 4.5.1), VOSviewer (version 1.6.19), and CiteSpace (version 6.4.R1). A total of 341 publications were retrieved from the WoSCC database and 624 from the Scopus database. Based on the combined analysis of both databases, the field exhibited a continuous upward trend in publication output. The top four countries in both databases were China, the USA, Germany, and Korea. China ranked first globally with 152 publications in WoSCC and 212 in Scopus, but its international co-authorship rates (13.2% and 17.5%, respectively) were markedly lower than those of the USA (34.4% and 34.9%) and Korea (40.0% and 33.3%). Molecular Therapy is the most influential core journal in this field. Research hotspots focus on four main areas: the mechanisms of oncolytic virus therapy for HCC, the evolution of genetically engineered armed vectors, combination therapies involving oncolytic viruses, and the challenges and breakthroughs in clinical translation. Future advances in this field will likely focus on three key directions: (1) optimizing transgene expression to balance antiviral and antitumor immunity; (2) developing personalized therapeutic strategies based on biomarkers such as immune cell subsets; (3) advancing clinical validation and regulatory approval of combination regimens through multicenter clinical studies. OV for HCC has entered a new integrated stage featuring mechanistic innovation, vector optimization, and precise combination therapy. The clear future directions can provide a well-defined roadmap for clinical translation, which is expected to yield more effective novel therapeutic strategies for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.